STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive

Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

Researchers explore possibility of a CTE blood test

Patient safety chief concerned about NHS Grampian

Some doctors in Northern Ireland go on strike over pay
